Share of Biogen Idec ( BIIB) could move higher Monday after ISI Group biotech analyst Mark Schoenebaum upgraded the stock to a buy. "On the back of its new multiple sclerosis pill (BG-12), we now believe that Biogen can double EPS over the next 3-4 years, triple it over the next 5-6 years, and quadruple earnings over a 6-7 year horizon," said Schoenebaum in an email to clients Sunday. Radient Pharmaceuticals ( RPC) faces a June 23 deadline to meet a list of financial requirements necessary to retain its listing on the AMEX. --Written by Adam Feuerstein in Boston. >To contact the writer of this article, click here: Adam Feuerstein. >To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein. >To submit a news tip, send an email to: firstname.lastname@example.org.